Cancer costs should be discussed by patients and providers, but information is not readily available. Results from recently published studies (in the last 5 years) on direct and indirect cancer costs may help guide these discussions. METHODS: The authors reviewed studies published between 2013 and 2017 that reported direct health care costs and indirect (productivity losses) costs. The annual mean total and net costs of cancer were summarized for all payers and for survivors only by age (ages 18-64 and ≥65 years), by phase of care (initial [ie, 12 months from diagnosis], continuing, and end-of-life [ie, 12 months before death]), or for recently diagnosed (within 1-2 years of diagnosis) and longer term survivors.
INTRODUCTION
In the United States, cancer care is transforming rapidly, with advances in treatment, increasing cost sharing among patients with health insurance, changing payment systems, and rising health care costs. An emergent cancer survivor population, comprising more than 15.5 million, 1 underscores the potential impact of cancer care on the health care system. A consensus is growing about the need for transparency and to integrate information about the cost of cancer care into patient-provider conversations to optimize medical decision making. [2] [3] [4] Recommendations are to provide patients and families with understandable information on out-of-pocket (OOP) costs and total costs of care. 5 The majority of individuals with cancer prefer to know and discuss costs of care with their providers, 6 -10 yet less than 1 in 5 report having cost discussions. 6, 7, 9 Consequently, many patients feel uninformed about the costs of their care 10 and face greater than expected OOP costs, 11 with the important material, psychological, and behavioral consequences of financial hardship. [12] [13] [14] [15] In addition to direct medical costs, patients experience other direct nonmedical costs to obtain care (eg, transportation) and indirect costs associated with productivity losses (Fig. 1 ). All components of economic burden may be considered in patient-provider cost discussions. Providing information about the costs of cancer and its care may foster informed decisions about treatment, 8 build patient-provider trust, 16 enable patients to budget for forthcoming costs, and improve patient outcomes. 17 Recently published studies may provide the information needed for initial discussions about the cancer costs to be expected in the short and long term. However, because these studies have varied widely with respect to population, payer perspective, timeframe, data source, cancer type, and cost component, a synthesis of their findings is needed. The objective of the current review was to summarize the existing knowledge about costs across the phases of cancer care, to evaluate its appropriateness to inform cost discussions, and to highlight areas where additional data are needed.
Additional supporting information may be found online in the Supporting Information section at the end of the article. 
METHODS
We conducted a thorough literature review and searched the PubMed, Scopus, Cochrane Library, and Business Source Premier databases for peer-reviewed articles providing estimates of OOP costs or total cancer care costs for adults in US settings. We limited our search to studies published in the most recent 5 years (2013) (2014) (2015) (2016) (2017) , with the exception of 1 earlier seminal publication 18 and 2 relevant studies known to the authors. 19, 20 Details of the search and the studies included are reported in the Supporting Information (see Supporting Materials, Supporting Fig. 1 , and Supporting Table 1 ). We included studies on direct health care costs and indirect costs incurred by survivors and/or health care payers (Fig. 1) . We used the National Cancer Institute's definition of survivorship as starting from the time of diagnosis. 21 We considered direct costs as those incurred to obtain care, including: 1) medical (ie, payments to providers by health care payers and survivors through deductibles, copayments, and coinsurance), and 2) nonmedical (eg, transportation costs) and time (ie, value of time to travel, wait, and receive care) costs incurred by survivors. 22 Indirect costs refer to productivity losses caused by missed work, lost household productivity, or disability related to the inability to be employed because of illness: we assumed that these costs were incurred only by survivors.
We narratively summarized costs for older (aged ≥65 years) and working-age (aged 18-64 years) adults and, when possible, by phase of care. Data from studies using registry-claims-linked databases are summarized by initial (usually 12 months after diagnosis), continuing, and end of life (usually 12 months before death) phases of care. Results of studies without a verified diagnosis date are reported separately for more recently diagnosed (within 2 years of diagnosis) and longer term survivors when possible. We provide annual cost estimates, unless otherwise noted. Estimates are reported as in the original studies: when available, we report adjusted estimates and net costs (ie, incremental costs incurred by survivors compared with similar counterparts without a cancer diagnosis). Quantitative synthesis was not feasible because of heterogeneity in data sources, the services included, and the methods used to identify cancer survivors.
RESULTS
Of 30 studies included, 9 were for populations aged ≥65 years only, 8 were for populations aged 18 to 64 years, and 13 were for populations spanning both age groups. Most studies (n = 26) provided data on direct health care costs, and 7 reported indirect costs.
Costs for Older Cancer Survivors (Aged ≥65

Years)
Direct health care costs to all payers
In the initial phase of care, annual net costs to all payers for cancers most common among women (breast, colorectal, lung, uterus, melanoma, lymphoma, leukemia, pancreas, and kidney) 23 were wide ranging, from $5047 for melanoma to $93,462 for pancreatic cancer, with approximately $23,000 for breast cancer (2010 US dollars) ( Table 1) . 18 Net costs for the most frequent cancers among men (prostate, lung, colorectal, bladder, melanoma, lymphoma, leukemia, and kidney) 23 were similarly wide ranging, from $5437 for melanoma to $60,885 for lung cancer, with $19,710 for prostate cancer. 18 Depending on the stage of disease, breast cancer net monthly costs ranged from $1886 (stage I) to $3627 (stage IV; 2015 US dollars) ( Table 1) . 19 Monthly costs of prostate cancer were lower, from <$800 (stage I) to $1342 (stage IV); whereas colorectal and lung cancers had higher Cancer November 1, 2018 costs, starting at $2289 per month for stage I colorectal cancer and >$5000 for stage IV disease. 19 Other cancer studies reported similar cost amounts paid by Medicare only. Direct costs declined in the continuing phase between diagnosis and end of life, but varied widely (Table 1 ). For the most common cancers among women, net annual costs to all payers ranged from $915 per year for melanoma to $8762 for pancreatic cancer, with approximately $2200 for breast cancer (2010 US dollars) ( Table 1) . 18 For the cancers most common among men, costs ranged from $1951 for melanoma to $10,249 for leukemia, with prostate cancer costs at approximately $3200. Costs also varied by stage at diagnosis. 19 At the end of life, annual net costs for most common cancers among women ranged from $56,784 for melanoma to $130,131 for leukemia. In 1 study of uterine cancer, median costs were >$9000 in the last month of life. 29 Among men, costs ranged from approximately $43,000 (2008 US dollars) 28 for prostate cancer to $133,183 for leukemia (2010 US dollars) 18 ( Cancer November 1, 2018 than the costs for respondents without cancer, respectively. 32 33 In contrast, OOP costs were $3737 in the overall study population. 33 Annual time costs for MEPS respondents with cancer were estimated at $913 (at a median wage of $16.57 per hour in 2011 US dollars) and were because of provider visits for most survivors and less common (but time-consuming) ambulatory surgeries, hospitalizations, and emergency room visits (Table 2) . 20 In contrast, annual time costs for respondents without a history of cancer were $607.
Indirect costs to survivors
Among recently diagnosed survivors, Guy et al reported an average of 11.4 missed work days, corresponding to a loss of $1109, and 16.6 days of lost household productivity, corresponding to a loss of $674 (Table 2) . 32 For survivors who were unable to work because of illness (12.9%), the disability loss in 1 year was $4350, compared with $3777 among MEPS respondents without a history of cancer. 32 Among longer term survivors, productivity losses were lower, but disability losses were similar. 32 Among breast, prostate, and colorectal cancer survivors, net productivity losses ranged from $30 to $221 for missed work days, and from $55 to $224 for lost household productivity. Disability losses were not significantly different from those among respondents without cancer (Table 2) . 35 Higher losses were reported in another study of prostate cancer survivors in which, using higher wages than in the previous 2 studies, the authors calculated losses of $2652 for missed work days and $20,034 for disability. 
Direct health care costs to all payers
For the initial and end-of-life phases of care, net costs for working-age cancer survivors reported by Mariotto et al were estimated by applying ratios of costs for older and younger adults obtained from earlier studies in managedcare settings, reflecting costs that typically were higher for working-age survivors than for older cancer survivors ( Table 3) . 18 Accordingly, net costs were wide ranging, similar to those for older adults, but were slightly higher overall. 18 In the initial phase of care, Banegas and colleagues reported net monthly costs ranging from $1099 for stage I prostate cancer to $7500 for stage IV breast and lung cancers (2015 US dollars) ( Table 3) . 19 Among North Carolina breast cancer survivors, yearly costs for private payers were >$75,000, and those for Medicaid were >$28,000 in 6 months (2014 US dollars) (Table 3) . 38, 39 Among women with de novo metastatic breast cancer, costs were $9955 per month over a mean follow-up of 332 days from diagnosis. 40 Similar to the older population, costs were lower in the continuing phase of care (Table 3) . 18, 19 Monthly net costs were up to 9 times higher for those with stage IV versus stage I disease. 19 At the end of life, annual costs were 2 or 3 times higher than those in the initial phase, as reported by Mariotto et al 18 ; and net monthly costs ranged from approximately $4500 to $9000, depending on stage, as reported by Banegas et al (Table 3) . 19 For Medicaid populations in Georgia and Illinois, net costs were $9814 for the 4 months before death (2003 US dollars). 41 Other findings from claims databases included costs >$60,000 for breast cancer survivors in the first year after the first claim with the relevant diagnosis code 42, 43 and lower costs for women during the period from 13 to 24 months after the index date. 42 Guy et al reported annual costs to all payers of $17,170 for recently diagnosed survivors and considerably lower costs for longer term survivors, although these were still higher than the costs among those without a history of cancer (Table 3) . 32 By using MEPS data that were not stratified by time from diagnosis, Ekwueme et al reported costs to all payers of approximately $8000 for men and women with cancer, which were $3000 to $5000 higher Cancer November 1, 2018 than the costs to counterparts without a history of cancer (2011 US dollars). 48 Net costs for breast, prostate, and colorectal cancers ranged from $3586 for prostate cancer to $8647 for colorectal cancer (2012 US dollars).
35
Direct health care OOP costs to survivors
Most information on OOP costs comes from survey-based studies (Table 4 ). In the MEPS data, annual OOP medical costs were $1107 for recently diagnosed survivors and $747 for longer term survivors, compared with $617 for those without a history of cancer (2010 US dollars). 32 Similar OOP costs were reported for men and women, 48 and similar net costs were reported for breast, prostate, and colorectal cancers. 35 For breast cancer survivors within 3 years of completing treatment, Pisu et al reported OOP costs that survivors attributed to cancer. Costs of medical care, including transportation costs, ranged from $129 to $149 per month over 1 year. 50 Survivors also reported costs of counseling and health maintenance ranging from $88 to $167 per month, costs of side-effect management ranging from $38 to $59 per month, and costs for home maintenance ranging from $138 to $186. 49 Annual time costs were $500, ranging from $1188 for those recently diagnosed and from $459 to $630 for longer term survivors (Table 4) . 20 These costs were because of provider visits for many survivors and less common (but time-consuming) ambulatory surgeries, hospitalizations, and emergency room visits. In contrast, annual time costs for respondents without a history of cancer were $226.
Indirect costs to survivors
Among recently diagnosed survivors, Guy et al reported an average of 16.9 missed work days (productivity loss, $1644), 9.5 lost household productivity days (productivity loss, $386), and 7.9% of survivors were unable to work (disability loss, $2664) ( Table 4) . 32 Among longer term survivors, there were 4.6 missed work days (productivity loss, $447), 7.7 lost household productivity days (productivity loss, $313), and 8.4% survivors were unable to work (disability loss, $2833). 32 Similar results were reported by Ekwueme et al 48 and Zheng et al, 35 whereas greater productivity losses were reported in other studies of breast cancer 50, 51 and colorectal cancer 52 survivors.
DISCUSSION
In our thorough review of recent studies describing total and OOP costs along the cancer care continuum, we observed that, depending on age and disease stage, the net cost to all payers of common cancers can be expected to be between $20,000 and $100,000 in the initial year after diagnosis and ≥$60,000 at the end of life. In the period between the first year after diagnosis and the end of life, costs are generally lower but also vary widely, ranging between $1000 and $30,000 per year. Costs can be considerably higher for less common cancers like ovarian and pancreatic malignancies. Costs incurred by survivors follow a similar pattern, with lower annual medical and time costs as well as productivity and disability losses among longer term survivors compared with more recently diagnosed survivors. OOP costs for medical care range from 7% to 11% of medical costs for all payers. 30, 32, 35, 48 Preventing or mitigating the effects of financial hardship from cancer is a clinical imperative. Such hardship is prevalent: approximately 1 in 2 survivors report financial distress. 12 Cancer costs impact patients and families, 53 regardless of insurance status, and have consequences in terms of sacrifices to cover these expenses. 13, 54, 55 Financial hardship is associated with poor treatment adherence, 56 worse symptoms and poor quality of life, 57, 58 and even shorter survival. 59 Understanding cancer costs has multiple potential benefits in this respect. For example, it can assist with planning and budgeting for the treatment and survivorship phases, facilitate an early connection with financial support services, or encourage discussions with providers about altering treatment and supportive care plans. When possible, providers may explore changes in medication brand, doses, or frequency, or they may avoid unnecessary services to improve affordability. 60 In these cases, a clear assessment of costs can act as a catalyst for physicians to discuss options with their patients: this is increasingly considered an integral part of high-quality cancer care, 9, 61 and it is consistent with patient preferences to discuss treatment costs at the time of treatment decision making. 8, 10, [62] [63] [64] [65] Full discussions of all aspects of economic burden may also improve the survivorship care-planning process.
The information presented here provides an overview of cancer costs; however, its usefulness in informing cost discussions is subject to several limitations. First, most studies were not designed to inform cost-of-care discussions in the clinical setting, so some limitations may apply primarily when considering the data for this purpose. Many claim-based studies include data that can be more than 10 years old and will not reflect current patterns of care. Historically, hospitalizations have been the largest driver of cancer costs; but, with increasingly expensive cancer therapies (eg, immunotherapy), prescription drugs and outpatient care will play an increasing role in costs. More current estimates that reflect current Cancer November 1, 2018
patterns of care are needed to enable useful patient-provider communication. Household survey-based studies likely understate payer and survivor OOP costs, because they may under-represent cancer survivors with a poor prognosis and higher cost cancers. Furthermore, within cancer types, the costs reported varied in methodology, timeframe, and data source. With regard to time and indirect cost estimates, some overlap is possible: for example, some of the time reported as missed days of work could be time spent at the physician's office. Therefore, these estimates should not be summed together to calculate a total time cost associated with cancer. Finally, because of our inclusion and exclusion criteria, the current review is not exhaustive, and we may have missed some studies or other gray literature with useful cost information. The body of evidence reviewed also has several notable gaps. Most studies report costs for health care payers. In particular, information about survivors' OOP costs in the first year of diagnosis and at the end of life was missing. Because OOP costs are approximately 10% of all payers' costs, survivors could be responsible for more than $10,000 in the first year after diagnosis based on the data presented here. With coinsurance rates ranging from 20% to 40%, and with some treatment costs rising above $100,000, OOP costs may become even more overwhelming, even potentially prohibitive, for many survivors. Several other factors put survivors at risk of high costs in addition to age and stage, including oral treatment, 66, 67 use of supportive care (such as growth factors and antiemetics 68, 69 ), survivors' overall health and comorbidities, 30, 31, 70, 71 and the type of insurance coverage and benefit design. 31, 33 Therefore, cancer-specific, stage-specific, and risk factor-specific cost estimates may be needed if data are to be optimally useful for clinicians and patients. Furthermore, information was limited on the nonmedical and time costs incurred by survivors during cancer care, such as transportation, child care, and time away from work: estimates of these costs would be useful if shared with survivors.
In conclusion, the costs of cancer to payers and survivors vary directly by age, stage, and cancer type and are highest in the initial treatment period and at the end of life. The information currently available in the research literature may have limited value for patient-provider discussions and does not include all costs incurred by survivors; however, it does provide some perspective on the magnitude of cancer costs along the care continuum. Efforts to describe up-to-date and comprehensive cost information are needed to support cost conversations; these may include, for example, local initiatives to routinely 
